Biotech Values

[DewDiligence]

Re: Neoantigen vaccines /ADXS-NEO

Curious that the authors of the Nature write-up you posted consider colorectal cancer to be a high-mutation cancer; it is generally thought to be the opposite.

Colorectal cancer will be one of the three indications for the ADXS-NEO neoantigen-vaccine program licensed by AMGN (the other two are NSCLC and H&N: #msg-134949543). According to ADXS’ FY4Q17 CC, the rationale for selecting colorectal cancer is to see if NEO can work in a “cold tumor” setting.